Division of Clinical Research, National Hospital Organization Kikuchi Hospital, 208 Fukuhara, Koshi, Kumamoto 861-1116, Japan.
Psychiatry Clin Neurosci. 2010 Apr;64(2):207-10. doi: 10.1111/j.1440-1819.2010.02072.x.
The aim of the present study was to investigate the efficacy of Yokukansan in improving behavioral symptoms of frontotemporal dementia. This study was a prospective, open-label trial of daily Yokukansan for 4 weeks in 20 frontotemporal dementia patients. Yokukansan treatment was found to significantly improve scores for the Neuropsychiatric Inventory and the Stereotypy Rating Inventory. No adverse effects or significant changes in physical findings and laboratory data occurred except for hypokalemia in two cases. The results indicate that Yokukansan can alleviate the behavioral symptoms of frontotemporal dementia. (The clinical trial registration number is UMIN000002704).
本研究旨在探讨和汉生改善额颞叶痴呆行为症状的疗效。这是一项前瞻性、开放标签的试验，对 20 例额颞叶痴呆患者给予和汉生每日治疗 4 周。研究发现，和汉生治疗可显著改善神经精神问卷和刻板行为评定量表的评分。除了 2 例出现低钾血症外，无不良反应或身体检查和实验室数据的显著变化。结果表明，和汉生可以缓解额颞叶痴呆的行为症状。（临床试验注册号：UMIN000002704）
